BIOSIMILAR Brenzys (etanercept) from MSD Australia is the subject of a new online course provided by the Pharmacy Guild of Australia to equip community pharmacists to manage issues around dispensing and consulting on biosimilar products.
Guild Learning and Development partnered with MSD Australia to develop the course titled 'Brenzys (etanercept): A guide for community pharmacists', the second to be launched on this topic, following the launch of a CPD accredited biosimilars course in Sep.
Brensyz is biosimilar to originator Pfizer brand Enbrel which was made available on the Pharmaceutical Benefits Scheme from 01 Apr 2017.
The Guild says this CPD activity has not been accredited by an authorised provider which means that pharmacists will need to assess it for suitability and relevance to determine if their individual learning needs will be addressed.
Visit myCPD.org.au or contact the Guild on 03 9810 9930.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Jan 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Jan 18
